References
- AielloLPBursellSEClermontAVascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitorDiabetes1997469147314809287049
- WildSRoglicGGreenASicreeRKingHGlobal prevalence of diabetes estimates for the year 2000 and projections for 2030Diabetes Care20042751047105315111519
- WeisSMChereshDAPathophysiological consequences of VEGF-induced vascular permeabilityNature2005437705849750416177780
- DvorakHFNagyJAFengDBrownLFDvorakAMVascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesisCurr Top Microbiol Immunol1999237971329893348
- IshidaSUsuiTYamashiroKVEGF164 is proinflammatory in the diabetic retinaInvest Ophthalmol Vis Sci20034452155216212714656
- QaumTXuQJoussenAMVEGF-initiated blood-retinal barrier breakdown in early diabetesInvest Ophthalmol Vis Sci200142102408241311527957
- TolentinoMJMcLeodDSTaomotoMOtsujiTAdamisAPLuttyGAPathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primateAm J Ophthalmol2002133337338511860975
- AminRHFrankRNKennedyAEliottDPuklinJEAbramsGWVascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathyInvest Ophthalmol Vis Sci199738136479008628
- FunatsuHYamashitaHNomaHMimuraTYamashitaTHoriSIncreased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edemaAm J Ophthalmol20021331707711755841
- Macugen® (pegaptanib sodium injection) [prescribing information]Palm Beach Gardens, FLEyetech Inc2011
- ReydermanLStavchanskySPharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in ratsPharm Res19981569049109647357
- GearyRSAntisense oligonucleotide pharmacokinetics and metabolismExpert Opin Drug Metab Toxicol2009538139119379126
- TuckerCEChenLSJudkinsMBFarmerJAGillSCDroletDWDetection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeysJ Chromatogr B Biomed Sci Appl1999732120321210517237
- HealyJMLewisSDKurzMPharmacokinetics and biodistribution of novel aptamer compositionsPharm Res200421122234224615648255
- MolitchMEDeFronzoRAFranzMJAmerican Diabetes AssociationNephropathy in diabetesDiabetes Care200427S79S8314693934
- LindemanRDTobinJShockNWLongitudinal studies on the rate of decline in renal function with ageJ Am Geriatr Soc19853342782853989190
- LoftusJVSultanMBPleilAMMacugen 1013 Study GroupChanges in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or shamInvest Ophthalmol Vis Sci201152107498750521896838
- BealSLSheinerLBBoeckmannABauerRJNONMEM User‘s Guides (1989–2009)Ellicott City, MDIcon Development Solutions2009
- MathSoft, IncS-Plus for WindowsSeattle, WAData Analysis Division, MathSoft, Inc2005
- AhnJEKarlssonMODunneALuddenTMLikelihood based approaches to handling data below the quantification limit using NONMEM VIJ Pharmacokinet Pharmacodyn200835440142118686017
- BealSLWays to fit a PK model with some data below the quantification limitJ Pharmacokinet Pharmacodyn200128548150411768292
- StratfordREJrCarsonLWDodda-KashiSLeeVHSystemic absorption of ocularly administered enkephalinamide and inulin in the albino rabbit: extent, pathways, and vehicle effectsJ Pharm Sci198877108388423236225
- KowalskiKGHutmacherMMEfficient screening of covariates in population models using Wald’s approximation to the likelihood ratio testJ Pharmacokinet Pharmacodyn200128325327511468940
- BasileASHutmacherMNickensDPopulation pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degenerationJ Clin Pharmacol20115281186119921947371
- MorjariaRChongNVPharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edemaExpert Opin Drug Metab Toxicol20141081185119224856361